Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sharmila Patel & Mark R Player. (2008) Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opinion on Investigational Drugs 17:12, pages 1865-1882.
Read now
Read now
Takahiro Inoue, Takashi Kobayashi, Naoki Terada, Yosuke Shimizu, Toshiyuki Kamoto, Osamu Ogawa & Eijiro Nakamura. (2007) Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology & Metabolism 2:5, pages 689-704.
Read now
Read now
Elizabeth Rose Rayburn, Hui Wang & Ruiwen Zhang. (2006) Antisense-based cancer therapeutics: are we there yet?. Expert Opinion on Emerging Drugs 11:2, pages 337-352.
Read now
Read now
Articles from other publishers (18)
Cindy Jacobs, Monica Krieger, Patricia S. Stewart, Karen D. Wisont & Scott Cormack. 2018. Oligonucleotide-Based Drugs and Therapeutics. Oligonucleotide-Based Drugs and Therapeutics
331
353
.
Sohaib Al-Asaaed & Eric Winquist. (2012) Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer. Current Oncology Reports 15:2, pages 113-118.
Crossref
Crossref
Yoshihiko Kadowaki, Nikhil S. Chari, Albert E. K. Teo, Akihiko Hashi, Kevin B. Spurgers & Timothy J. McDonnell. (2011) PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells. Apoptosis 16:6, pages 627-635.
Crossref
Crossref
Maximino Redondo, Rafael Fùnez & Francisco Esteban. 2009. Apoptosis in Carcinogenesis and Chemotherapy. Apoptosis in Carcinogenesis and Chemotherapy
237
249
.
Frank Alexis, June-Wha Rhee, Jerome P. Richie, Aleksandar F. Radovic-Moreno, Robert Langer & Omid C. Farokhzad. (2008) New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations 26:1, pages 74-85.
Crossref
Crossref
Bin Liu, Mei Han, Jin-Kun Wen & Ling Wang. (2007) Livin/ML-IAP as a new target for cancer treatment. Cancer Letters 250:2, pages 168-176.
Crossref
Crossref
Beatrice S. Knudsen & Cindy K. Miranti. (2006) The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. Journal of Cellular Biochemistry 99:2, pages 345-361.
Crossref
Crossref
L R Kidd, A Coulibaly, T M Templeton, W Chen, L O Long, T Mason, C Bonilla, F Akereyeni, V Freeman, W Isaacs, C Ahaghotu & R A Kittles. (2006) Germline BCL-2 sequence variants and inherited predisposition to prostate cancer. Prostate Cancer and Prostatic Diseases 9:3, pages 284-292.
Crossref
Crossref
C. Gennigens, C. Menetrier-Caux & J.P. Droz. (2006) Insulin-Like Growth Factor (IGF) family and prostate cancer. Critical Reviews in Oncology/Hematology 58:2, pages 124-145.
Crossref
Crossref
Sylvie Lamy, Marcia T. Ruiz, Jan Wisniewski, Seema Garde, Shafaat A. Rabbani, Chandra Panchal, Jinzi J. Wu & Borhane Annabi. (2006) A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis. International Journal of Cancer 118:9, pages 2350-2358.
Crossref
Crossref
Howard I. Scher & Charles L. Sawyers. (2005) Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. Journal of Clinical Oncology 23:32, pages 8253-8261.
Crossref
Crossref
Molly Kulesz-Martin, James Lagowski, Suzanne Fei, Carl Pelz, Rosalie Sears, Marianne Broome Powell, Ruth Halaban & Jodi Johnson. (2005) Melanocyte and Keratinocyte Carcinogenesis: p53 Family Protein Activities and Intersecting mRNA Expression Profiles. Journal of Investigative Dermatology Symposium Proceedings 10:2, pages 142-152.
Crossref
Crossref
Matthew R. Smith & Joel B. Nelson. (2005) Future therapies in hormone-refractory prostate cancer. Urology 65:5, pages 9-16.
Crossref
Crossref
John M. Strother, Tomasz M. Beer & Robert Dreicer. (2005) Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?. European Journal of Cancer 41:6, pages 954-964.
Crossref
Crossref
Mark F. McCarty. (2016) Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy. Integrative Cancer Therapies 3:4, pages 349-380.
Crossref
Crossref
Robert DiPaola. 2004. Management of Prostate Cancer. Management of Prostate Cancer
339
366
.
P.D. Rye & T. Stigbrand. (2004) Interfering with Cancer: A Brief Outline of Advances in RNA Interference in Oncology. Tumor Biology 25:5-6, pages 329-336.
Crossref
Crossref
Yoko Funasaka, Hirofumi Sato, Ashok K. Chakraborty, Akiko Ohashi, George P. Chrousos & Masamitsu Ichihashi. (1999) Expression of Proopiomelanocortin, Corticotropin-Releasing Hormone (CRH), and CRH Receptor in Melanoma Cells, Nevus Cells, and Normal Human Melanocytes. Journal of Investigative Dermatology Symposium Proceedings 4:2, pages 105-109.
Crossref
Crossref